BioLineRx (BLRX) Short-term Investments (2012 - 2025)

BioLineRx's Short-term Investments history runs 14 years deep, the most recent figure standing at $17.6 million for Q4 2025.

• In Q4 2025, Short-term Investments rose 93.14% year-over-year to $17.6 million; the TTM figure through Dec 2025 stood at $17.6 million (up 93.14% YoY), while the FY2025 annual figure was $17.6 million, up 93.14% from the prior year.
• Short-term Investments was $17.6 million for Q4 2025 at BioLineRx, up from $17.3 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $48.1 million in Q3 2021 to a low of $9.1 million in Q4 2024.
• Historically, Short-term Investments has averaged $30.2 million across 5 years, with a median of $29.8 million in 2022.
• The sharpest annual moves came in 2021 and 2024: Short-term Investments soared 666.94% in 2021, then slumped 76.44% in 2024.
• A 5-year view of Short-term Investments shows it stood at $44.1 million in 2021, then retreated by 8.27% to $40.5 million in 2022, then retreated by 4.34% to $38.7 million in 2023, then plunged by 76.44% to $9.1 million in 2024, then jumped by 93.14% to $17.6 million in 2025.
• The last three Short-term Investments figures came in at $17.6 million (Q4 2025), $17.3 million (Q3 2025), and $21.0 million (Q2 2025), per Business Quant data.